deltatrials
Terminated PHASE3 NCT00180544

Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease

A Prospective, Non-Randomized, Multicenter, Single-Arm, Clinical Trial to Assess the Safety and Efficacy of the RX HERCULINK 14 Peripheral Stent System for Treatment in de Novo or Restenotic Renal Artery Stenosis

Sponsor: Abbott Medical Devices

Conditions Renal Artery Obstruction
Interventions Stenting: Renal Artery
Updated 11 times since 2017 Last updated: Jul 24, 2008 Started: Jul 31, 2000 Primary completion: Aug 31, 2004 Completion: Aug 31, 2004

A PHASE3 clinical study on Renal Artery Obstruction, this trial is terminated or withdrawn. The trial is conducted by Abbott Medical Devices and has accumulated 11 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE3

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE3

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE3

▶ Show 6 earlier versions

  1. Dec 2018 — Nov 2020 [monthly]

    Terminated PHASE3

  2. Jun 2018 — Dec 2018 [monthly]

    Terminated PHASE3

  3. May 2018 — Jun 2018 [monthly]

    Terminated PHASE3

  4. Aug 2017 — May 2018 [monthly]

    Terminated PHASE3

  5. Feb 2017 — Aug 2017 [monthly]

    Terminated PHASE3

  6. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE3

    First recorded

Jul 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abbott Medical Devices
Data source: Abbott Medical Devices

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New Orleans, United States